Sign In
Buy PTC
$139.72
-2.62 (-1.84%)
At Close: Jun 03, 2026
PTC ANNOUNCES THIRD FISCAL QUARTER 2024 RESULTS
04:01pm, Wednesday, 31'st Jul 2024
Solid ARR and Cash Flow in Q3'24 Guiding to 11-12% Constant Currency ARR Growth and Maintaining Free Cash Flow Guidance for FY'24 BOSTON , July 31, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
09:45am, Wednesday, 31'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to
What Are the Hottest IoT Stocks Right Now? 3 Top Picks.
06:07am, Wednesday, 31'st Jul 2024
In its broadest sense, the Internet of Things (IoT) means anything that can be connected to the internet. Think your bread toaster, wearable items, your fridge and even your dog collar all connected t
What Analyst Projections for Key Metrics Reveal About PTC Inc. (PTC) Q3 Earnings
10:21am, Tuesday, 30'th Jul 2024
Get a deeper insight into the potential performance of PTC Inc. (PTC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
08:00am, Tuesday, 30'th Jul 2024
WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA.
PTC Gears Up to Report Q3 Earnings: What's in the Offing?
10:40am, Monday, 29'th Jul 2024
PTC's fiscal third-quarter performance is likely to have been driven by strong business pipeline activities across the PLM and CAD segments despite forex fluctuations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
10:30am, Friday, 26'th Jul 2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
04:30pm, Thursday, 25'th Jul 2024
WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2024 financial res
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
08:00pm, Wednesday, 24'th Jul 2024
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to
PTC Inc. (PTC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Wednesday, 24'th Jul 2024
PTC Inc. (PTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
03:45pm, Tuesday, 23'rd Jul 2024
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
03:53pm, Saturday, 20'th Jul 2024
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investor
Why PTC Inc. (PTC) Could Beat Earnings Estimates Again
01:16pm, Friday, 19'th Jul 2024
PTC Inc. (PTC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
06:26pm, Thursday, 18'th Jul 2024
NEW YORK , July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
12:00pm, Sunday, 14'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to
